Home › Calculator › SBHMY Dividend Calculator 2026
SBHMY DRIP Calculator & Dividend Yield 2026
2.02% YieldHealthcareSino Biopharmaceutical Limited · OTC
Price: $12.67 · Annual div: $0.2561/share · Frequency: annual · Payout ratio: 10% · Ex-div: 2026-09-02
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When SBHMY pays your bills
Year your monthly dividend income covers each expense (based on current settings)
SBHMY Dividend History — Last 23 Payments
| Ex-Dividend Date | Payment Date | Amount / Share | TTM Yield | Stock Price |
|---|---|---|---|---|
| 2026-09-02Latest | 2026-10-09 | $0.1785 | 2.35% | $13.01 |
| 2026-06-25 | 2026-08-04 | $0.1275 | 1.79% | $14.28 |
| 2025-08-29 | 2025-10-08 | $0.1286 | 1.65% | $18.65 |
| 2025-06-17 | 2025-07-25 | $0.1019 | 1.89% | $9.48 |
| 2024-09-11 | 2024-10-18 | $0.0772 | 2.56% | $8.00 |
| 2024-06-12 | 2024-07-22 | $0.0768 | 3.91% | $7.20 |
| 2023-10-04 | 2023-11-13 | $0.0511 | 2.84% | $7.22 |
| 2023-06-20 | 2023-07-31 | $0.1536 | 3.31% | $9.27 |
| 2022-09-06 | 2022-10-13 | $0.1529 | 2.81% | $10.88 |
| 2022-06-15 | 2022-07-27 | $0.1019 | 2.47% | $10.38 |
| 2021-09-10 | 2021-10-19 | $0.0514 | 1.55% | $16.59 |
| 2021-06-17 | 2021-07-27 | $0.1030 | 0.92% | $22.50 |
| 2020-12-11 | 2021-01-15 | $0.0516 | — | — |
| 2020-09-11 | 2020-10-15 | $0.0516 | — | — |
| 2020-06-11 | 2020-07-21 | $0.0688 | — | — |
| 2019-12-09 | 2020-01-13 | $0.0342 | — | — |
| 2019-09-11 | 2019-10-15 | $0.0340 | — | — |
| 2019-06-13 | 2019-07-19 | $0.0340 | — | — |
| 2018-12-04 | 2019-01-07 | $0.0340 | — | — |
| 2018-09-10 | 2018-10-15 | $0.0340 | — | — |
| 2018-06-01 | 2018-07-10 | $0.0680 | — | — |
| 2017-11-27 | 2018-01-02 | $0.0683 | — | — |
| 2017-09-15 | 2017-10-16 | $0.0341 | — | — |
About Sino Biopharmaceutical Limited (SBHMY) — Dividend Analysis 2026
Sino Biopharmaceutical Limited operates as a prominent research and development-centric pharmaceutical conglomerate in the People's Republic of China, functioning as an investment holding company. Its operations are organized into three primary divisions: Modernized Chinese and Chemical Medicines, Investment activities, and other varied business ventures. The firm maintains an extensive product range covering numerous therapeutic categories. Among its offerings are oncology treatments, such as Qingkeshu tablets and Leweixin injections; cardiovascular and cerebrovascular medications, including Kaina and Anrixin tablets; hepatitis remedies like Tianqingganmei injections; and orthopedic solutions exemplified by Gaisanchun capsules. The company also produces drugs for respiratory ailments and parenteral nutritional support, for instance, Xinhaineng injections, along with a broad spectrum of other pharmaceutical preparations, such as Tuotuo tablets. Additionally, Sino Biopharmaceutical provides a selection of advanced pharmaceutical agents, including Aprepitant, Lenvatinib Mesilate, Vortioxetine Hydrobromide, and Edaravone injection. Its portfolio also features combination therapies like Amlodipine Besylate and Atorvastatin Calcium, alongside Sofosbuvir, Sitagliptin Phosphate, Colistimethate Sodium for injection, and Tofacitinib Citrate. Beyond its core pharmaceutical manufacturing, the company's diverse business interests encompass property holdings, the retail and distribution of pharmaceutical products, and providing optometry services coupled with the sale of ophthalmic goods. It manages hospitals, delivers medical management and health information consultancy, and offers biotechnology transfer and consultation services. The enterprise is also involved in the production and sale of health foods, provides orthopedic outpatient care and surgical procedures, engages in medical and health technology development, trades optical glasses, and conducts research, development, and commercialization of medical devices and active pharmaceutical ingredients. Established in 2000, the company's corporate headquarters are situated in Wan Chai, Hong Kong.
Similar dividend stocks to SBHMY
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full SBHMY DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open SBHMY position with:
🌍 SBHMY Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold SBHMY.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2.02% | -0.78% | $202 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 1.72% | -1.08% | $172 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1.62% | -1.18% | $162 / yr |
| 🇬🇧 UK ISA | 0% | 2.02% | -0.78% | $202 / yr |
| 🇬🇧 UK Taxable | 8.75% | 1.84% | -0.96% | $184 / yr |
| 🇨🇦 TFSA | 0% | 2.02% | -0.78% | $202 / yr |
| 🇨🇦 CA Taxable | 25% | 1.52% | -1.28% | $152 / yr |
| 🇦🇺 Super (pension) | 15% | 1.72% | -1.08% | $172 / yr |
| 🇦🇺 AU Taxable | 30% | 1.41% | -1.39% | $141 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1.49% | -1.31% | $149 / yr |
| 🇫🇷 FR Taxable | 30% | 1.41% | -1.39% | $141 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 SBHMY Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.26/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 SBHMY Dividend Payment Schedule
SBHMY pays quarterly — 4 times per year. Ex-div: 2026-09-02.
📊 SBHMY vs Healthcare Benchmarks
How SBHMY compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SBHMY sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ SBHMY Insider Activity
No recent SEC filings reported in the last 90 days.Peer Group
Similar companies in the same sectorCompare SBHMY with peers: SBHMY vs ALPMF · SBHMY vs ALPMY · SBHMY vs BMXXY
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SBHMY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Sino Biopharmaceutical Limited (SBHMY) is currently trading at $12.67, 35% below its 52-week high. The current dividend yield is 2.02% based on an annual payout of $0.2561 per share.
SBHMY (Sino Biopharmaceutical Limited) — 2.02% Dividend Yield Analysis
Sino Biopharmaceutical Limited (SBHMY) is a healthcare stock currently trading at $12.67 with a dividend yield of 2.02%. It pays an annual dividend of $0.2561 per share. The payout ratio of 10% suggests the dividend is well-covered by earnings. Over the past 5 years, SBHMY has grown its dividend at a compound annual rate of 5.7%.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest SBHMY News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.
How investors use the SBHMY dividend calculator
Illustrative examples of common use cases, written by the DividendFlow team — not customer reviews.